Sino Biopharmaceutical Ltd - Company Profile
Powered by 
All the sales intelligence you need on Sino Biopharmaceutical Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sino Biopharmaceutical Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sino Biopharmaceutical Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sino Biopharmaceutical Ltd (Sino Biopharma) is a research-oriented pharmaceutical company that develops, manufactures, and markets medicines, biopharmaceuticals, and Chinese medicines. The company focuses on advancing therapies across oncology, liver and cardiometabolic diseases, respiratory and autoimmune diseases, and surgery and analgesia. Sino Biopharma offers medicines for the treatment of cancer, hepatitis and liver conditions, cardiovascular and metabolic disorders, respiratory illnesses, autoimmune diseases, and postoperative pain. It offers products in various dosage forms including large-volume injections, PVC-free soft bags for intravenous injections, small-volume injections, powdered medicines, granulated medicines, capsules, and tablets. Sino Biopharma is headquartered in Wanchai, Hong Kong.
Headquarters
Hong Kong
Address
Unit 09, 41f, Office Tower, Convention Plaza, No. 1 Harbour Road, Wanchai, Hong Kong City
Website
www.sinobiopharm.com
Telephone
852 28029886
No of Employees
22,838
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1177 (HKG)
Revenue (2024)
$4.4B
10.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-33%
(2024 vs 2023)
Market Cap*
$13.6B
Net Profit Margin (2024)
XYZ
-39.3%
(2024 vs 2023)
* As of and is in US$
Sino Biopharmaceutical Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oncology | Focus V |
| Focus V (Anlotinib Hydrochloride Capsules) | Annike |
| Annike (Penpulimab Injection) | Yilishu |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In September, the company entered into a strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group to promote innovative R&D and commercial networks. |
| 2026 | Regulatory Approval | In August, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. received approval from the National Medical Products Administration for LM-364 Nectin4TMEADC to treat advanced solid tumors. |
| 2026 | Regulatory Approval | In August, Beijing Tide Pharmaceutical received US FDA approval for its CPX301 soluble microneedle patch for weight management. |
Competitor Comparison
| Key Parameters | Sino Biopharmaceutical Ltd | China Resources Pharmaceutical Group Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | The United Laboratories International Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | Hong Kong | China | China | Hong Kong |
| City | Hong Kong City | Hong Kong City | Shanghai | Lianyungang | Hong Kong City |
| State/Province | - | - | Shanghai | Jiangsu | - |
| No. of Employees | 22,838 | 84,000 | 40,603 | 20,602 | 18,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tse, Eric S Y | Chief Executive Officer; Director | Executive Board | 2022 | 30 |
| Theresa Tse | Chairwoman | Executive Board | 2015 | 33 |
| Kang Xiaoyan | Chief Medical Officer | Senior Management | 2026 | - |
| Hsin Tse | Director; Senior Vice President | Executive Board | - | 56 |
| Tian Zhoushan | Director | Executive Board | - | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer